相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
News Item
Multidisciplinary Sciences
Ewen Callaway
Editorial Material
Medicine, General & Internal
Elizabeth G. Phimister
Summary: The production of mRNA vaccines against SARS-CoV-2 set a record in 11 months, but the preclinical research behind it spanned decades and faced challenges due to lack of funding. The 2021 Lasker-DeBakey Clinical Medical Research Award was given to Drs. Drew Weissman and Katalin Kariko, pioneer researchers of modified RNA.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Ben Y. Reis et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Guy Witberg et al.
Summary: Among 2.5 million patients who received the BNT162b2 mRNA vaccine in a large Israeli health care system, the incidence of myocarditis at 42 days was 2.13 cases per 100,000 persons, with the highest incidence (10.69 per 100,000 persons) among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Ai-ris Y. Collier et al.
Summary: The kinetics of immune response to Covid-19 vaccines were studied, showing varying peak levels and durations of response for different vaccines. However, the response levels correlating with protection have not been defined yet.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Elizabeth T. Chin et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
News Item
Medicine, General & Internal
[Anonymous]
MEDICAL JOURNAL OF AUSTRALIA
(2021)
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
D. Mevorach et al.
Summary: The incidence of myocarditis increased after receiving the BNT162b2 vaccine in Israel, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Aharona Glatman-Freedman et al.
Summary: The BNT162b2 vaccine in Israel showed high effectiveness in preventing new SARS-CoV-2 cases. Effectiveness of the vaccine develops more slowly in individuals over 80 years old. Vaccination reduces complications and death in breakthrough cases.
Article
Medicine, General & Internal
Eleftheria Vasileiou et al.
Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.
Article
Medicine, General & Internal
Eric J. Haas et al.
Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Medicine, General & Internal
Tom T. Shimabukuro et al.
Summary: Preliminary data indicates that there are no obvious safety signals among pregnant women who received mRNA Covid-19 vaccines, but more data is needed for further confirmation. Adverse reactions such as injection-site pain were reported more frequently in pregnant women, but most pregnancies resulted in live births with some cases of preterm birth and small size for gestational age.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Elizabeth M. White et al.
Summary: The study found that incident SARS-CoV-2 infections decreased significantly after mRNA vaccination in nursing homes, with most infections being asymptomatic.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Madhumita Shrotri et al.
Letter
Medicine, General & Internal
Aziz Sheikh et al.
Editorial Material
Multidisciplinary Sciences
Andreas Radbruch et al.
Article
Multidisciplinary Sciences
Jackson S. Turner et al.
Summary: SARS-CoV-2 mRNA vaccines induce a persistent germinal centre B cell response in humans, leading to the generation of robust humoral immunity, especially more significant in individuals previously infected with the virus.
Article
Multidisciplinary Sciences
Valerie Oberhardt et al.
Summary: After vaccination, CD8(+) T cells become important effector cells in providing early protection, being effectively mobilized one week after primary vaccination and maintaining stability after booster vaccination. Compared with natural infection, vaccine-induced CD8(+) T cells exhibit similar functional capacities but with a different subset distribution.
News Item
Multidisciplinary Sciences
Elie Dolgin
News Item
Multidisciplinary Sciences
Elie Dolgin
Summary: Scientists are searching for explanations to disappointing final-stage trial results in order to guide the future development of mRNA vaccines.
Article
Biochemistry & Molecular Biology
Hiam Chemaitelly et al.
Summary: A study showed that the mRNA-1273 vaccine is highly effective against the B.1.1.7 and B.1.351 variants of concern, with efficacy rates of 100% and 96.4% respectively. The vaccine's effectiveness increases rapidly in the weeks following the first dose, reaching maximum efficacy after the second dose, providing strong protection against severe COVID-19 outcomes.
Article
Biochemistry & Molecular Biology
Noa Dagan et al.
Summary: The BNT162b2 COVID-19 vaccine showed high effectiveness in pregnant women in an observational cohort study in Israel, similar to the effectiveness seen in the general population.
Letter
Medicine, General & Internal
Amanda K. Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Natalie E. Dean et al.
Summary: Observational studies are becoming crucial for assessing vaccine effectiveness, especially when large randomized controlled trials are not feasible. These studies can monitor vaccine efficacy waning and assess the effectiveness against new coronavirus variants.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Kashif Ali et al.
Summary: The study demonstrates that the mRNA-1273 vaccine has good safety profile in adolescents aged 12 to 17 years, with immune response similar to that in young adults. It also proves the efficacy of the vaccine in preventing Covid-19 in this age group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Robert W. Frenck et al.
Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
T. Pilishvili et al.
Summary: The BNT162b2 and mRNA-1273 vaccines were highly effective in preventing symptomatic Covid-19 in U.S. health care personnel, with vaccine effectiveness of 77.6% to 96.3%. The effectiveness was consistent across different subgroups defined by age, race and ethnic group, underlying conditions, and patient contact levels, indicating the vaccines were effective for preventing Covid-19 in those at risk and in disproportionately affected groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Lauren H. Zauche et al.
Summary: The risk of spontaneous abortion in early pregnancy after receiving mRNA Covid-19 vaccination is consistent with historical data.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Ann R. Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
M. G. Thompson et al.
Summary: A study with a test-negative design analyzed 41,552 admissions to 187 hospitals and 21,522 visits to 221 EDs or urgent care clinics. The mRNA-based vaccines (>= 14 days after the second dose) were highly effective against SARS-CoV-2 infection leading to hospitalization (89%), ICU admission (90%), or an urgent care visit (91%).
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noam Barda et al.
Summary: The study found that after receiving the BNT162b2 vaccine, most adverse events were not associated with an increased risk, although there was a slight increase in the risk of myocarditis. On the other hand, infection with the Covid-19 virus significantly increased the risk of many serious adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Mark G. Thompson et al.
Summary: The study demonstrated that COVID-19 mRNA vaccines were highly effective in preventing SARS-CoV-2 infection in real-world conditions, while also attenuating the viral RNA load, febrile symptoms, and illness duration among vaccinated individuals who had breakthrough infections.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
H. M. El Sahly et al.
Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Amarendra Pegu et al.
Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.
Article
Multidisciplinary Sciences
Jose Mateus et al.
Summary: This study examined the immune responses to the Moderna mRNA-1273 vaccine over 7 months, finding that subjects with preexisting cross-reactive T cell memory exhibited stronger CD4(+) T cell and antibody responses to the vaccine. This demonstrates the biological relevance and potential importance of cross-reactive T cells in generating immunity to SARS-CoV-2.
Article
Multidisciplinary Sciences
Kizzmekia S. Corbett et al.
Summary: In nonhuman primates (NHPs), vaccination with mRNA-1273 induces dose-dependent antibody responses, leading to a significant reduction in viral replication post SARS-CoV-2 challenge. Replication of the virus correlates strongly with antibody levels and neutralizing activity, with lower levels required in the lower airway than in the upper airway. Passive transfer of mRNA-1273-induced IgG is sufficient to provide protection, indicating that humoral immune responses induced by mRNA-1273 vaccine are effective against SARS-CoV-2 in NHPs.
Article
Medicine, General & Internal
Peter G. Kremsner et al.
Summary: The RNActive technology platform was used to prepare CVnCoV, a COVID-19 vaccine containing optimized mRNA encoding for a stabilized form of SARS-CoV-2 spike protein. The dosage escalation phase 1 study showed that 12 µg of CVnCoV vaccine elicited immune responses comparable to those seen in convalescent sera from COVID-19 patients, with acceptable safety and reactogenicity.
WIENER KLINISCHE WOCHENSCHRIFT
(2021)
Article
Multidisciplinary Sciences
Donata Hoffmann et al.
Summary: The study demonstrates that two spike encoding mRNA vaccines provide effective protection against the variants of concern B.1.351 and the ancestral strain BavPat1 of SARS-CoV-2, despite lower neutralizing antibody titers against B.1.351.
NATURE COMMUNICATIONS
(2021)
Article
Otorhinolaryngology
Asaf Shemer et al.
Summary: This case-control study found no association between recent vaccination with the BNT162b2 vaccine and the risk of facial nerve palsy. The analysis of data from previous years also showed a relatively stable trend in the number of admissions for facial nerve palsy patients.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2021)
Letter
Medicine, General & Internal
Maria C. Magnus et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)